Report : Europe Cardiac Microcatheter Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Indication (General Peripheral Vascular and Coronary) and End User (Hospitals, Specialty Clinics, and Ambulatory Surgical Centers)
At 6.4% CAGR, the Europe Cardiac Microcatheter Market is speculated to be worth US$ 134.83 million by 2028, says Business Market Insights
According to Business Market Insights research, the Europe cardiac microcatheter market was valued at US$ 98.64 million in 2023 and is expected to reach US$ 134.83 million by 2028, registering a CAGR of 6.4% from 2023 to 2028. High prevalence of cardiovascular diseases and growing use of percutaneous coronary intervention (PCI) for treating chronic total occlusions (CTO) are the critical factors attributed to the Europe cardiac microcatheter market expansion.
As a coronary interventional tool, microcatheters support the performance of invasive endovascular procedures by fulfilling a wide range of functions in complex vascular anatomies. Manufacturers across the world are investing in research and development of advanced technologies, which has led to the development of new and advanced products, along with a surge in product approvals. A few product approvals and developments are listed below: In 2019, Navitian, a new coronary microcatheter from iVascular, received the CE mark approval. The device was approved to facilitate, guide, and support a guidewire while accessing the coronary system, exchanging guidewires, and injecting radiopaque contrast media or saline solutions. In 2021, Baylis Medical unveiled the first clinical case of the JLL 2-French electrophysiology microcatheter in Europe. The launch enables physicians to reach previously inaccessible areas of the heart for procedure mapping, thereby introducing the smallest diagnostic catheter available in the European market. The 2F microcatheter also allows mapping and pacing in smaller anatomy, such as the Vein of Marshall. In 2020, Acist Medical Systems Inc., a Bracco Group Company, announced the global launch of its Acist Navvus II Rapid Exchange fractional flow reserve (FFR) microcatheter, the second-generation microcatheter for use with its Acist RXi Rapid Exchange FFR System. FFR measurements assess arterial lesion severity and the intervention strategies in diagnosing and treating coronary artery disease. Therefore, a surge in new product approvals, launches, and awareness in the field of cardiac microcatheter is expected to fuel the cardiac microcatheter market growth during the forecast period.
On the contrary, complications and failures related to usage of cardiac microcatheters hampers the Europe Cardiac Microcatheter Market.
Based on indication, the Europe cardiac microcatheter market is segmented into general peripheral vascular and coronary. The coronary segment held 58.1% share of Europe Cardiac Microcatheter Market in 2023, amassing US$ 57.27 million. It is projected to garner US$ 78.94 million by 2028 to expand at 6.6% CAGR during 2023–2028.
Based on end user, the Europe cardiac microcatheter market is segmented into hospitals, specialty clinics, and ambulatory surgical centers. The hospitals segment held 44.7% share of Europe Cardiac Microcatheter Market in 2023, amassing US$ 44.23 million. It is projected to garner US$ 61.41 million by 2028 to expand at 6.8% CAGR during 2023–2028.
Based on country, the Europe cardiac microcatheter market has been categorized into the U.K., Germany, France, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 27.5% share of Europe Cardiac Microcatheter Market in 2023. It was assessed at US$ 27.13 million in 2023 and is likely to hit US$ 38.17 million by 2028, exhibiting a CAGR of 7.1% during the forecast period.
Key players dominating the Europe cardiac microcatheter market are Boston Scientific Corp; Integer Holdings Corp; Medtronic Plc; Merit Medical Systems Inc; Nipro Corp; and Terumo Corp, among others.
- In July 2021, Terumo Medical Corporation (TMC) announced AZUR Vascular Plug, the first and only plug compatible with a microcatheter to occlude arteries up to 8mm in diameter. The newest addition to Terumo's robust embolization portfolio is indicated for use to reduce or block the blood flow rate in peripheral vasculature arteries.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com